PUBLISHER: DelveInsight | PRODUCT CODE: 1462311
PUBLISHER: DelveInsight | PRODUCT CODE: 1462311
"PF-07923568 Market Size, Forecast, and Emerging Insight - 2032" report provides comprehensive insights about PF-07923568 for Respiratory syncytial virus (RSV) in the seven major markets. A detailed picture of the PF-07923568 for RSV in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the PF-07923568 for RSV. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the PF-07923568 market forecast analysis for RSV in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in RSV.
PF-07923568 is an orally bioavailable inhibitor of respiratory syncytial virus (RSV) fusion that was identified after a lead optimization process based upon hits that originated from a physical property directed hit profiling exercise at Reviral. This exercise encompassed collaborations with a number of contract organizations with collaborative medicinal chemistry and virology during the optimization phase in addition to those utilized as the compound proceeded through preclinical and clinical evaluation.
It is an orally administered inhibitor designed to block fusion of the RSV virus to the host cell currently in Phase II clinical development for both adult and pediatric populations.
The report provides insights into:
The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.
PF-07923568 Analytical Perspective by DelveInsight
This report provides a detailed market assessment of PF-07923568 for Respiratory syncytial virus (RSV) in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2027 to 2032.
The report provides the clinical trials information of PF-07923568 for RSV covering trial interventions, trial conditions, trial status, start and completion dates.